medigraphic.com
Centro de Investigaciones Regionales Dr. Hideyo Noguchi, Universidad Autónoma de Yucatán

2005, Number 1

<< Back Next >>

Rev Biomed 2005; 16 (1)

Influenza and vaccination.

Piñón- Ramos A, Oropesa-Fernández S, Aragonés-López C, Galindo B, Acosta-Herrera B, Hernández-Espinosa B

Language: Spanish
References: 115
Page: 45-54
PDF size: 53.04 Kb.


ABSTRACT

Until the advent of AIDS, influenza was the last uncontrolled pandemic killer of humans. One historic measure the potential lethality of influenza is that more people died in the 1918-19 pandemic than in World War I.
Influenza type A and B viruses are responsible for widespread illness in people. Influenza is an acute respiratory disease caused by Influenza type A or B viruses. The incubation period ranges from 1-4 days. Peak virus shedding usually occurs from 1 day to 3 days after. Typical features of Influenza include abrupt onset of fever and respiratory symptoms such as cough (usually nonproductive), sore throat, and coryza, as well as systemic symptoms such as headache, muscle aches, and fatigue. The clinical severity of infection can range from asymptomatic illness to primary viral pneumonia and death. Acute symptoms generally last 2-4 days although malaise and cough may continue for up to 2 weeks. Complications of Influenza include secondary bacterial pneumonia and exacerbation of underlying chronic health conditions.
The best way to prevent influenza infection is vaccination. Vaccination works by exposing our immune systems to an inactivated strain of the virus that cannot cause disease. Annual vaccination against Influenza is recommended for people at high risk for Influenza-associated complications and their close contacts. Each year influenza vaccinations save thousands of lives and much suffering. The World Health Organization (WHO) strongly recommends the influenza vaccination for those at risk from influenza infection. This is the most effective means of reducing the impact of Influenza.
In Cuba, Influenza and pnemumonia are the fifth cause of death. In our country we vaccinate people in high risk groups. With the objective of determining aspects about Influenza vaccines we carried out the present study.


REFERENCES

  1. 1.- Karzon DT. Cytotoxic T cells in influenza immunity. Semin Virol 1996; 7:265-71.

  3. 2.- Reed WP, Olds JW, Kisch AI. Decreased skin-test reactivity associated with influenza. J Infect Dis 1972; 125:398-402.

  5. 3.- Wright PF, Webster, RG. Orthomyxoviruses. In: Knipe DM, Howley PM, ed. Fields virology. Philadelphia: Lippincontt Williams and Wilkins; 2001. 1:1533-79.

  7. 4.- Lamb RA, Krug, RM. Orthomyxoviridae: the viruses and their replication. In: Knipe DM, Howley PM, ed. Fields virology. Philadelphia: Lippincott Williams and Wilkins; 2001. 1:1487-531.

  9. 5.- Okuno, Y. Examination and vaccination against influenza. Rinsho Byori 2003; 51:268-73.

  11. 6.- Hilleman MR. Current overview of the pathogenesis and prophylaxis of measles with focus on practical implications. Vaccine 2002; 20:652-65.

  12. 7.- McDonnell WM, Askari FK. DNA vaccines. N Engl J Med 1996; 334:42-5.

  14. 8.- Ulmer JB. Influenza DNA vaccines. Vaccine 2002; 20 (Suppl 2):S74-6.

  16. 9.- Ljungberg K, Wahren B, Almqvist J, Hinkula J, Linde A, Winberg G. Effective construction of DNA vaccines against variable influenza genes by homologous recombination. Virology 2000; 268:244-50.

  18. 10.- Monto AS. Prospects for pandemic influenza control with currently available vaccines and antivirals. J Infect Dis 1997; 176 (Suppl 1):S32-7.

  20. 11.- Draft WHO guidelines on the use of vaccines and antivirals during influenza pandemics. Wkly Epidemiol Rec 2002; 77:394-404.

  22. 12.- Bui M, Whittaker G, Helenius A. Effect of M1 protein and low pH on nuclear transport of influenza virus ribonucleoproteins. J Virol 1996; 70:8391-401.

  24. 13.- Hay AJ. The action of adamantanamines against influenza A viruses: inhibition of the M2 ion channel protein. Semin Virol 1992; 3:21-30.

  26. 14.- Suzuki K, Torii M, Yamamoto T, Mizuno Y. Prevention and care management of influenza infection in institutions for the elderly and high risk groups. Nippon Rinsho 2000; 58:2327-32.

  28. 15.- Brydak LB, Machala M. Humoral immune response to influenza vaccination in patients from high risk groups. Drugs 2000; 60:35-53.

  30. 16.- Costa TX, Rodriguez AA, Perez PN, Begines CM, Cabello ORC, Romero GA. Influenza vaccination in high-risk groups. Role of the nursing staff. Aten Primaria 1994; 13:256-8.

  32. 17.- Hilleman MR. Realities and enigmas of human viral influenza: pathogenesis, epidemiology and control. Vaccine 2002; 20:3068-87.

  34. 18.- Sugaya N. Influenza. Nippon Rinsho 2003; 61 (Suppl 2):135-40.

  36. 19.- Fukumi H. History of influenza vaccine. Uirusu 1985; 35:107-22.

  38. 20.- Smorodintsev AA. History of the study of the etiology and vaccinal prevention of influenza (scientific contribution of Tushinskii's clinic). Klin Med (Mosk) 1982; 60:108-12.

  39. 21.- Merten OW, Hannoun C, Manuguerra JC, Ventre F, Petres, S. Production of influenza virus in cell cultures for vaccine preparation. Adv Exp Med Biol 1996; 397: 141-51.

  41. 22.- Tree JA, Richardson C, Fooks AR, Clegg JC, Looby D. Comparison of large-scale mammalian cell culture systems with egg culture for the production of influenza virus A vaccine strains. Vaccine 2001; 19(25-26): 3444-50.

  43. 23.- Schoenbaum SC, Mostow SR, Dowdle WR, Coleman MT, Kaye HS. Studies with inactivated influenza vaccines purified by zonal centrifugation. 2. Efficacy. Bull WHO 1969; 41:531-5.

  45. 24.- Kanarek AD, Tribe GW. The preparation of viral vaccines containing purified extracted antigens. Prog Immunobiol Stand 1969; 3:165-9.

  47. 25.- Eckert EA. Envelope protein of influenza virus. II. Antigenicity. Arch Environ Health 1970; 21:316-20.

  49. 26.- Johansson BE, Pokorny BA, Tiso VA. Supplementation of conventional trivalent influenza vaccine with purified viral N1 and N2 neuraminidases induces a balanced immune response without antigenic competition. Vaccine 2002; 20:1670-4.

  51. 27.- Three new flu vaccines. Drug Ther Bull 1977; 15:103-4.

  53. 28.- Stohr K. Preventing and treating influenza. Br Med J 2003; 326:1223-4.

  55. 29.- Minutello M, Senatore F, Cecchinelli G. Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons. Vaccine 1999; 17:99-104.

  57. 30.- Ben-Yehuda A, Joseph A, Barenholz Y. Immunogenicity and safety of a novel IL-2-supplemented liposomal influenza vaccine (INFLUSOME-VAC) in nursing-home residents. Vaccine 2003; 21:3169-78.

  59. 31.- Fridman EA, Peradze TV. Effectiveness of inactivated vaccines against influenza. Tr Inst Im Pastera 1982; 58:84-94.

  61. 32.- Avratinskii IM, Stepankovskaia LD, Katuntsevskaia GP. The evaluation of the efficacy of repeated inoculations against influenza using inactivated vaccines. Lik Sprava 1992:79-81.

  63. 33.- Baldo V, Menegon T, Buoro S. Vaccination against influenza in the elderly. Experience with adjuvant vaccines. Ann Ig 1999; 11:369-74.

  65. 34.- Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine 2001; 19:2673-80.

  67. 35.- Belshe RB, Couch RB, Glezen WP, Treanor JT. Live attenuated intranasal influenza vaccine. Vaccine 2002; 20:3429-30.

  69. 36.- Bernstein DI, Yan L, Treanor J, Mendelman PM, Belshe R. Effect of yearly vaccinations with live, attenuated, cold-adapted, trivalent, intranasal influenza vaccines on antibody responses in children. Pediatr Infect Dis J 2003; 22:28-34.

  71. 37.- Zangwill KM. Cold-adapted, live attenuated intranasal influenza virus vaccine. Pediatr Infect Dis J 2003; 22:273-4.

  73. 38.- Wareing MD, Tannock GA. Live attenuated vaccines against influenza; an historical review. Vaccine 2001; 19:3320-30.

  75. 39.- Ulmer JB, Deck RR, Yawman A. DNA vaccines for bacteria and viruses. Adv Exp Med Biol 1996; 397:49-53.

  77. 40.- Wolff JA, Malone RW, Williams P, Chang W, Acsadi G, Jani A, et al. Direct gene transfer into mouse muscle, in vivo. Science 1990; 247:1465-8.

  79. 41.- Liu MA, McClements W, Ulmer JB, Shiver J, Donnelly J. Immunization of non-human primates with DNA vaccines. Vaccine 1997; 15:909-12.

  81. 42.- Okuda K, Ihata A, Watabe S, Okada E, Yamakawa T, Hamasima K, et al. Protective immunity against influenza A viruses induced by immunization with DNA plasmid containing influenza M gene. Vaccine 2001; 19:3681-91.

  83. 43.- Zebedee FL, Lamb RA. Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions. J Virol 1988; 62:2762-72.

  85. 44.- Treanor JJ, Tierney EL, Zebedee SL, Lamb RL, Murphy BR. Passively Transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice. J Virol 1990; 64:1375-7.

  87. 45.- Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 1999; 5:1157-63.

  89. 46.- Anke H, Laura B, Wouter TV, Marijke H, Toos D, Abraham M, et al. Influenza virosomes: combining optimal presentation of hemagglutinin with immunopotentiating activity. Vaccine 2003; 21:925-31.

  91. 47.- Cox NJ, Subbarao K. Influenza. Lancet 1999; 354:1277-82.

  93. 48.- Potter CW, Oxford JS. Determinants of immunity to influenza infection in man. Br Med Bull 1979; 35:69-75.

  95. 49.- Nichol KL, Margolis KL, Wuorenma J, Von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 1994; 331:778-84.

  97. 50.- Drinka PJ, Gravenstein S, Krause P, Schilling M, Miller BA, Shult P. Outbreaks of influenza A and B in a highly immunized nursing home population. J Fam Pract 1997; 45:509-14.

  99. 51.- Ohmit SE, Arden NH, Monto AS. Effectiveness of inactivated influenza vaccine among nursing home residents during an influenza type A (H3N2) epidemic. J Am Geriatr Soc 1999; 47:165-71.

  101. 52.- Belshe RB, Mendelman PM, Treanor J. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med 1998; 338:1405-12.

  103. 53.- Mayor S. Flu experts warn of need for pandemic plans. Bmj 2000; 321:852.

  105. 54.- WHO tags 1999-2000 vaccine, prepares flu pandemic plan. Public Health Rep 1999; 114:211.

  107. 55.- Cox NJ, Brammer TL, Regnery HL. Influenza: global surveillance for epidemic and pandemic variants. Eur J Epidemiol 1994; 10:467-70.

  109. 56.- De Jong JC, Rimmelzwaan GF, Fouchier RA, Osterhaus AD. Influenza pandemics: past and future. Ned Tijdschr Geneeskd 1999; 143:1988-91.

  111. 57.- Das P. Flu experts fear countries are unprepared for a future pandemic. Lancet 2001; 357:1419.

  113. 58.- Fedson DS. Pandemic influenza and the global vaccine supply. Clin Infect Dis 2003; 36:1552-61.

  115. 59.- Fukuda K. Are we ready for emerging strains of pandemic influenza? Int J Clin Pract Suppl 2000:37-43.




2020     |     www.medigraphic.com